Skip to content

Interest Income at other companies

Incyte logo
IncyteINCY
$33.69M+46.9%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$22.56M+18.7%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$6.25M+16.0%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$2.79M+17.0%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$3.56M-50.4%
Bicara Therapeutics logo
Bicara TherapeuticsBCAX
$4.08M-18.6%

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.81B+318%
Enterprise value$1.73B+397%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Reported directly by Tyra Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestAndOtherIncome.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s interest income?
Tyra Biosciences, Inc. (TYRA) reported interest income of $2.69M in Q1 2026.
How has Tyra Biosciences, Inc.'s interest income changed year-over-year?
Tyra Biosciences, Inc.'s interest income decreased by 27.3% year-over-year, from $3.7M to $2.69M.
What is the long-term trend for Tyra Biosciences, Inc.'s interest income?
Over 2 years (2023 to 2025), Tyra Biosciences, Inc.'s interest income has grown at a 8.9% compound annual growth rate (CAGR), from $10.81M to $12.82M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.